DNAPrint Selects Proteos To Manufacture PT-401 For Preclinical Evaluation
(EMAILWIRE.COM, June 14, 2005 ) Lake Harmony, PA -- DNAPrint Genomics, Inc. (OTC BB: DNAP) today announced that it has selected Proteos, Inc. to manufacture the first batch of its new therapeutic candidate PT-401 (Super EPO dimer) for pre-clinical testing.
"Proteos has 20 years of experience in protein and peptide chemistry and has proven its ability as a Contract Research Organization (CRO) dealing with biologically complex therapeutics," stated DNAPrint Chief Medical Officer Hector Gomez, M.D., Ph. D. "The selection of Proteos is the culmination of a competitive bidding process solicited by DNAPrint management. In addition, Proteos' staff has previously worked with erythropoietin (EPO), the simpler, monomer form of the drug that major pharmaceutical companies currently have on the market."
For more information visit http://www.vlcn.com/dnap61405.htm.
TheNewsWire Top Winners are Travelzoo Inc (Nasdaq: TZOO), Santarus Inc (Nasdaq: SNTS), drugstore.com inc (Nasdaq: DSCM), Optical Cable Corp (Nasdaq: OCCF), Airnet Communications Corp (Nasdaq: ANCC), Presidential Life Corp (Nasdaq: PLFE), Royale Energy Inc (Nasdaq: ROYL) and Diodes Inc (Nasdaq: DIOD).
TheNewsWire Top Losers are GigaMedia Ltd (Nasdaq: GIGM), US Energy Corp (Nasdaq: USEG), WPCS Intl Inc (Nasdaq: WPCS), Internet Initiative Japan Inc (Nasdaq: IIJI), Vivus Inc (Nasdaq: VVUS), Workstream Inc (Nasdaq: WSTM), Cardiodynamics International Corp (Nasdaq: CDIC) and Imperial Industries (Nasdaq: IPII).
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. The company has hired and paid $595.00 for the publication and circulation of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity and no representation.
Contact:
C.P. Barry
Company: http://www.TheNewsWire.com
Phone: 1.888.478.7669
Source: TheNewsWire.com
"Proteos has 20 years of experience in protein and peptide chemistry and has proven its ability as a Contract Research Organization (CRO) dealing with biologically complex therapeutics," stated DNAPrint Chief Medical Officer Hector Gomez, M.D., Ph. D. "The selection of Proteos is the culmination of a competitive bidding process solicited by DNAPrint management. In addition, Proteos' staff has previously worked with erythropoietin (EPO), the simpler, monomer form of the drug that major pharmaceutical companies currently have on the market."
For more information visit http://www.vlcn.com/dnap61405.htm.
TheNewsWire Top Winners are Travelzoo Inc (Nasdaq: TZOO), Santarus Inc (Nasdaq: SNTS), drugstore.com inc (Nasdaq: DSCM), Optical Cable Corp (Nasdaq: OCCF), Airnet Communications Corp (Nasdaq: ANCC), Presidential Life Corp (Nasdaq: PLFE), Royale Energy Inc (Nasdaq: ROYL) and Diodes Inc (Nasdaq: DIOD).
TheNewsWire Top Losers are GigaMedia Ltd (Nasdaq: GIGM), US Energy Corp (Nasdaq: USEG), WPCS Intl Inc (Nasdaq: WPCS), Internet Initiative Japan Inc (Nasdaq: IIJI), Vivus Inc (Nasdaq: VVUS), Workstream Inc (Nasdaq: WSTM), Cardiodynamics International Corp (Nasdaq: CDIC) and Imperial Industries (Nasdaq: IPII).
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. The company has hired and paid $595.00 for the publication and circulation of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity and no representation.
Contact:
C.P. Barry
Company: http://www.TheNewsWire.com
Phone: 1.888.478.7669
Source: TheNewsWire.com
Contact Information:
OTC Report
Joseph Nchor
Tel:
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
OTC Report
Joseph Nchor
Tel:
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |